By: Gretchen Stipec, M.D., radiologist, Cancer Institute, Long Beach Medical Center Seniors account for nearly 28% of all new ...

MENLO PARK, Calif., Oct. 17, 2025 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive ...

Grail (NASDAQ:GRAL) announced Wednesday that its Galleri test led to improved cancer detection when added to standard-of-care cancer screening in its PATHFINDER 2 registrational trial. Citing topline ...

CHICAGO -- Hundreds of people using the test company Grail were wrongly told they might have cancer, the company said in a statement Monday. Grail said a software glitch related to their telemedicine ...

GRAIL's Galleri test offers multi-cancer early detection, validated by large clinical studies and over 370,000 tests sold since 2021. The company was spun out of Illumina, then reacquired for $8bn, ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. As part of its bid to transform the future of cancer screening and seize control of ...

SAN FRANSISCO, CA, UNITED STATES, November 7, 2025 /EINPresswire.com/ -- GenieMD today announced it will integrate GRAIL’s groundbreaking Galleri ® multi-cancer ...

GRAIL Inc. (NASDAQ:GRAL) is one of the best young stocks to buy and hold for 5 years. On June 18, GRAIL announced positive top-line performance and safety results from the pre-specified analysis of ...

First PATHFINDER 2 Results Accepted as a Late-Breaking Presentation at the European Society for Medical Oncology (ESMO) Congress 2025; Results to be Submitted to FDA as Part of the Galleri Premarket ...

Grail is partnering with Samsung to move into Asia. The innovative cancer test maker just got major new sources of funding. Well, Grail makes a multicancer early-detection test called Galleri that ...